Rushang Patel, MD

Medical Director (Stem Cell Transplant and Cellular Therapy), Hematology Oncologist

Clinical Cancer Research

Expertise of Rushang Patel, MD

Biography: Rushang Patel, MD completed fellowships in bone marrow transplant at Temple University and in hematology/oncology at Fox Chase Cancer Center, one of only 21 prestigious National Comprehensive Cancer Networks (NCCN) in the country. Board-certified in internal medicine and board eligible in medical oncology and hematology, Dr. Patel brings a wealth of clinical knowledge and in-depth research experience to both patient and practice, having worked on projects for United Nations International Children's Emergency Fund (UNICEF), Alembic Pharmaceuticals and Sanofi-Aventis, as well as having conducted studies focused on the mechanisms of cancer formation due to toxic chemicals and identifying new targets for designing cancer drugs
Education: Baroda Medical College, Vadodara, Gujarat
Residency: Abington Memorial Hospital, Abington, PA
Fellowship: Temple University, Philadelphia, PA
Specialty: Bone Marrow Transplant
Board Certifications: American Board of Internal Medicine

Publications

A Phase 2, Single-Arm, Multicohort, Open Label, Multicenter Trial of Off-the-Shelf Natural Killer Cells (SAR445419) in Patients with High-Risk Myeloid Malignancies Undergoing Allogeneic HSCT

2023, BLOOD
Evaluation of different pharmacokinetically guided IV busulfan exposure ranges on adult patient outcomes after hematopoietic stem cell transplantation

2022, ANNALS OF HEMATOLOGY
Cryopreserved versus fresh peripheral blood allogeneic stem cell transplantation outcomes in patients receiving post-transplant cyclophosphamide for graft-versus-host prophylaxis during the COVID-19 pandemic: a single center experience

2022, INTERNATIONAL JOURNAL OF HEMATOLOGY

More sources loaded
Mutational profiling of myeloid neoplasms associated genes may aid the diagnosis of acute myeloid leukemia with myelodysplasia-related changes

2021, LEUKEMIA RESEARCH
Comparison of Myeloablative versus Reduced-Intensity Conditioning Regimens in Allogeneic Stem Cell Transplantation Recipients with Acute Myelogenous Leukemia with Measurable Residual Disease-Negative Disease at the Time of Transplantation: A Retrospective Cohort Study

2021, TRANSPLANTATION AND CELLULAR THERAPY
Impact of Next-Generation Sequencing Cell-free Pathogen DNA Test on Antimicrobial Management in Adults with Hematological Malignancies and Transplant Recipients with Suspected Infections

2021, TRANSPLANTATION AND CELLULAR THERAPY
Adverse Impact of DNA Methylation Regulatory Gene Mutations on the Prognosis of AML Patients in the 2017 ELN Favorable Risk Group, Particularly Those Defined by NPM1 Mutation

2021, DIAGNOSTICS
Conditioning regimen intensity and low-dose azacitidine maintenance after allogeneic hematopoietic cell transplantation for acute myeloid leukemia

2020, LEUKEMIA & LYMPHOMA
Eltrombopag for Treating Thrombocytopenia after Allogeneic Stem Cell Transplantation

2019, BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
Increased bone marrow CD56(bright) natural killer cells at 30 days after allogeneic stem cell transplantation associated with adverse patient outcome

2019, BONE MARROW TRANSPLANTATION

Associated Clinical Trials for Rushang Patel, MD

NCT06500273

A Randomized, Open-Label Study Evaluating the Efficacy and Safety of Cemacabtagene Ansegedleucel in Participants with Minimal Residual Disease after Response to First Line Therapy for Large B-Cell Lymphoma (ALPHA3)

This study is currently enrolling.

Associated Conditions: Lymphoma

Research Area: Clinical Cancer Research

Research Location: Orlando, Florida

The study is being conducted in patients diagnosed with large B-cell lymphoma who have completed initial therapy. The study aims to see if CAR T cells made from healthy donors are an effective...
NCT05332054

Long-Term Follow-up Study (LTFS): An Observational Long-term Follow-up Study of Patients Who Received Prior Caribou Cell Therapy

This study is currently enrolling.

Research Area: Clinical Cancer Research

Research Location: Orlando, Florida

Caribou's CAR-T cell product is a genetically modified cell therapy, meaning it is designed to change the expression of a gene or alter natural properties of living cells. Healthy donor T cells have...
NCT04637763

CB-010: A Phase 1, Multicenter, Open-Label Study of CB-010, a CRISPR-Edited Allogeneic Anti-CD19 CAR-T Cell Therapy in Patients with Relapsed/Refractory B Cell Non-Hodgkin Lymphoma (ANTLER)

This study is currently enrolling.

Research Area: Clinical Cancer Research

Research Location: Orlando, Florida

Allogeneic CAR-T cell therapy is a type of cancer therapy in which a healthy donor’s T cells (a type of immune system cell that circulates in blood) are modified during manufacturing using CRISPR...

More clinical trials loaded
NCT05653271

A Phase 1 Multicenter Study Evaluating the Safety and Efficacy of ACE1831, an Allogeneic CD20-conjugated gamma delta T-cell therapy, in Adult Subjects with Relapsed/Refractory CD20-expressing B-cell Malignancies

This study is currently enrolling.

Associated Conditions: Bone Cancer

Research Area: Clinical Cancer Research

A Phase 1 Multicenter Study Evaluating the Safety and Efficacy of
ACE1831, an Allogeneic CD20-conjugated gamma delta T-cell therapy, in Adult Subjects with Relapsed/Refractory CD20-expressing B-cell...
NCT05107856

A Phase 1, Open-Label, Multicenter, Dose Escalation Study of PRT1419 Injection in Patients with Relapsed/Refractory Hematologic Malignancies

This study is not currently enrolling.

Associated Conditions: Leukemia

Research Area: Clinical Cancer Research

The purpose of this research study is to test the safety of PRT1419 at different dose levels to find out what effects, good and/or bad, PRT1419 has on you and your type of cancer. The information...

Rushang Patel, MD

Expertise of Rushang Patel, MD

Associated Clinical Trials for Rushang Patel, MD

A Randomized, Open-Label Study Evaluating the Efficacy and Safety of Cemacabtagene Ansegedleucel in Participants with Minimal Residual Disease after Response to First Line Therapy for Large B-Cell Lymphoma (ALPHA3)

Long-Term Follow-up Study (LTFS): An Observational Long-term Follow-up Study of Patients Who Received Prior Caribou Cell Therapy

CB-010: A Phase 1, Multicenter, Open-Label Study of CB-010, a CRISPR-Edited Allogeneic Anti-CD19 CAR-T Cell Therapy in Patients with Relapsed/Refractory B Cell Non-Hodgkin Lymphoma (ANTLER)

A Phase 1 Multicenter Study Evaluating the Safety and Efficacy of ACE1831, an Allogeneic CD20-conjugated gamma delta T-cell therapy, in Adult Subjects with Relapsed/Refractory CD20-expressing B-cell Malignancies

A Phase 1, Open-Label, Multicenter, Dose Escalation Study of PRT1419 Injection in Patients with Relapsed/Refractory Hematologic Malignancies